ENDONOVO THERAPEUTICS, INC.: 10-Q/A filed 2013-06-21
What ENDONOVO THERAPEUTICS, INC. reported in its quarterly report amendment filed 2013-06-21 (fiscal Q1 2013): 21 published measures, 46 facts as tagged in accession 0001469709-13-000402.
This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.
This filing
- Form
- 10-Q/A (quarterly report amendment)
- Filed
- 2013-06-21
- Fiscal period
- fiscal Q1 2013
- Accession
- 0001469709-13-000402 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ENDONOVO THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 106,432 | USD | |
| At 2012-12-31 | 78,101 | USD | |
| At 2012-03-14 | 2,164 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 2,491,977 | USD | |
| At 2012-12-31 | 1,959,256 | USD | |
| At 2012-03-14 | 0 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | -2,385,545 | USD | |
| At 2012-12-31 | -1,881,155 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 32,754 | USD | |
| At 2012-12-31 | 800 | USD | |
| At 2012-03-31 | 51,977 | USD | |
| At 2011-12-31 | 9,247 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | -1,125,952 | USD | 90 |
| 2012-01-01 to 2012-03-31 | -430,784 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | -116,231 | USD | 90 |
| 2012-01-01 to 2012-03-31 | -20,318 | USD | 91 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 0 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 1,673 | USD | 91 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 148,185 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 10,000 | USD | 91 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 0 | USD | 90 |
| 2012-01-01 to 2012-03-31 | -53,048 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | -3,566,539 | USD | |
| At 2012-12-31 | -2,440,587 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 47,099,804 | shares | 90 |
| 2012-01-01 to 2012-03-31 | 40,472,391 | shares | 91 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 533 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 0 | USD | 91 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 61,678 | USD | |
| At 2012-12-31 | 65,301 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | -1,025,337 | USD | 90 |
| 2012-01-01 to 2012-03-31 | -425,541 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 32,754 | USD | |
| At 2012-12-31 | 800 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 2,267,433 | USD | |
| At 2012-12-31 | 1,752,600 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 1,025,337 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 427,214 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 61,153,823 | shares | |
| At 2012-12-31 | 53,692,673 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 1,174,878 | USD | |
| At 2012-12-31 | 554,062 | USD |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 0 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 3,950 | USD | 91 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 467,121 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 326,457 | USD | 91 |
Inspect the source
- Entity
- ENDONOVO THERAPEUTICS, INC. / CIK 0001528172
- Captured
- 2026-09-20T09:15:36.026Z
- SEC response SHA-256
77af3f2eba134146bbd094e17b18f0fd658f8dd873b389b6434b1de9b2ac5f8a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001528172.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))